ArticleVirus research2026
Hepatitis B virus RNA levels and clinical characteristics of persistent viremia in HBsAg-positive patients undergoing nucleos(t)ide analog.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to analyze serum HBV RNA levels in HBsAg-positive patients with persistent viremia undergoing nucleos(t)ide analog (NAs) therapy for over 48 weeks and to examine the clinical characteristics of HBV RNA-positive patients.
methodsIn this cross-sectional study, 277 patients with complete virological response (CVR) and 277 patients with persistent viral positivity (PV) were included, with confounders balanced using 1:1 propensity score matching (PSM). Serum HBV RNA levels were quantified using a PCR-fluorescent probe assay, with a lower limit of quantification of 100 copies/mL. Patients in the PV group were classified into RNA-negative (<100 copies/mL) and RNA-positive (≥100 copies/mL) subgroups based on RNA levels.
resultsThe HBV RNA-positive rate was significantly higher in the PV group than in the CVR group (P < 0.001). Multivariable regression analysis identified ALT, AST, HBsAg level, HBeAb status, and HBV RNA status as independent predictors of HBV DNA positivity. ALT levels were significantly higher in HBV RNA-positive patients, and the prevalence of cirrhosis and splenomegaly was notably higher in the RNA-positive group (P < 0.05), suggesting more severe liver damage. HBV RNA status was positively associated with HBsAg, HBeAg, and HBV DNA positivity.
conclusionHBV RNA status is an important marker of viral replication activity and liver injury, particularly in PV patients. Monitoring HBV RNA status as a non-invasive biomarker may help assess disease progression and inform patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.